2013 Annual Conference Welcome!
Nicole Robinson, Ph.D.
Assistant Vice President Center for Technology Commercialization
Cincinnati Children’s Hospital Medical Center
Matthew McFarland, RPh, Ph.D.
Director Office of Technology Commercialization
The Research Institute at Nationwide Children’s Hospital
Stephen Behm, MBA
Director, Technology Management, Center for Clinical Research and Technology,
University Hospitals Case Medical Center, Rainbow Babies and Children’s Hospital
Aris Eliades, PhD, RN, CNS
Associate Director, The Rebecca D. Considine Research Institute Director, Nursing Research, Akron Children’s Hospital
Aggregating World-Class Research
• Ohio is home to the largest sum of NIH funded pediatric research in the entire United States
• We brought more than $245 million to Ohio in 2011 through federal grants, foundation or philanthropic grants and industry partnerships
• We are leading the development of groundbreaking research and technology that create jobs and save children’s lives
• Ohio is the only state in the US with a flagship children’s hospital within two hours of every child
• Three of the nation’s seven largest (by bed count) children’s hospitals are located in Ohio – Cincinnati Children’s Hospital Medical Center – Nationwide Children’s Hospital – Akron Children’s Hospital
• Ohio is a pediatric health care destination, serving children from all
88 counties in Ohio, all 50 states and dozens of international countries
Aggregating World-Class Care
Collaborative Track Record
• Through our OCHA partnership, Ohio’s Medicaid costs for children are below the national average
• We are leading the country in pediatric quality of care and patient safety through the Solutions for Patient Safety
• Successful research and clinical collaboration through the Governor’s Medical Corridor initiative
Accelerating Commercialization
FY08-12
Research $ $1,845,760,413
Invention Disclosures 1054
Patent Applications 427
Patents Issued 167
Start-Up Companies 17
Licenses 158
Revenues $90,794,990
• Tech Transfer is Accelerating Efforts
• Growing Pipeline of Opportunities
• Leveraging Infrastructural and Community Assets
• Commercialization Successes are on the rise
Future Considerations
• Payment Reform: paying for value not volume
• Provider Cuts: Innovation and commercialization cannot happen without adequate infrastructure
• ACA Implications beyond Medicaid Expansion: exchange, market share, access issues
Clinical Trials Network, Access to Hospital Purchasing,
why more Pharmaceutical Companies will come to Ohio, and more
3:00 – 4:15
James Chmiel, MD, MPH
Director and Chief Executive, Ohio Clinical Trials Collaborative, Associate Professor of Pediatrics, Case
Western Reserve University School of Medicine, Clinical Chief, Division of Pediatric Pulmonology and
Allergy/Immunology, Rainbow Babies and Children’s Hospital
Jim Chmiel, MD, MPH Director and Chief Executive, OCTC
November 5, 2013
Ohio Clinical Trials Collaborative A statewide coordinating agency.
Ohio Medical Corridor Governor Kasich’s Statewide Initiative
Goal •Create jobs •Attract Investors •Improve the health of the citizens of Ohio and beyond •Advance medical science
Purpose •Influence collaboration and build upon our collective strength •Leverage the scientific expertise at the major research institutions in Ohio •Convene job-creating medical institutions to spark ideas •Attract additional medical companies and jobs to Ohio
Ohio Clinical Trials Collaborative (OCTC) •May 2013, State approves $1.98M to support startup funding for year one
About OCTC Not-For-Profit Agency Serving Biopharma and Healthcare Industries
LAUNCHED MAY 2013
SERVES
LEADS
PROVIDES
AS A CENTRAL AGENCY THAT OVERSEES A ROBUST CLINICAL TRIALS NETWORK ACROSS OHIO AND FACILITATES ACCESS TO AND ACCELERATING THE PERFORMANCE OF CLINICAL TRIALS
BUSINESS DEVELOPMENT, GLOBAL SALES, MARKETING, AND COMMUNICATIONS EFFORTS
COST-EFFECTIVE, QUALITY-DRIVEN SOLUTIONS TO DRUG MAKERS, BIOTECHS, DEVICE MAKERS, CROS, AND PATIENTS
Ohio Clinical Trials Collaborative
3-Clinical and Translational Science Awards (CTSA) Network
Cincinnati Children’s Hospital Medical Center
Cleveland Clinic Foundation
MetroHealth Medical Center
Nationwide Children’s Hospital
The Ohio State University Wexner Medical Center
Practice Based Research Network
University of Cincinnati Medical Center
University Hospitals Case Medical Center
Ohio Clinical Trials Collaborative
Founding Partners
Vision To establish Ohio as a national and global leader in attracting and successfully conducting clinical trials.
Mission To establish Ohio as one of the most efficient and effective states to test new medications and treatment strategies by simplifying and accelerating the delivery of innovative therapies and products to patients and build upon and expand the state’s biopharmaceutical sector.
27
Ohio Clinical Trials Collaborative
Ohio Clinical Trials Collaborative (OCTC) leverages $121M in NIH investment in
Ohio’s Clinical + Translational Science Awards Network
Ohio Clinical Trials Collaborative
Biohealth Business in Ohio - A World Leader
1st in the Midwest and 7th Nationally
1st Most Improved Business Climate (Chief Executive Magazine, 2013)
3rd Lowest Tax Rate on New Capital Investment
1st in the US World-renowned Cleveland Clinic’s heart, nephrology, and urology programs
3 of 7 Top US Pediatric Hospitals The most comprehensive network of children’s hospitals in the nation
8th in Bio-related Patents
Top 10 in US in Biotechnology Strength Positioned for continued growth in medical device design, manufacturing, R&D
New $500M Global Center for Healthcare Innovation: Patient-centered innovation and
commercialization powered by biomedical discovery and enterprise
• Cost-effective, quality-driven solutions to drug makers, biotechs, device makers, and CROs
• Cost-efficient, successful navigation of the clinical trial continuum
• Education and supervision needed to assist the statewide network and its clinical trial sites to ensure quality and increase success rates for biopharma companies and CROs
Ohio Clinical Trials Collaborative
OCTC Provides Industry Solutions
• Navigation of regulatory and ethical requirements of studies involving human subjects
• Accessing, recruiting, and retaining the desired patient populations
• Shortening the length of time it takes to start and complete trials
• Contracting
• Controlling rising financial costs
Ohio Clinical Trials Collaborative
OCTC Provides Industry Solutions
Ohio Clinical Trials Collaborative
Leadership Founder
Pamela B. Davis, MD, PhD Clinical and Translational Science Collaborative Case Western Reserve University, Cleveland, Ohio
Co-founder
Rebecca Jackson, MD The Ohio State University Center for Clinical and Translational Science Ohio State University, Columbus, Ohio
Co-founder
James E. Heubi, MD Center for Clinical and Translational Science and Training University of Cincinnati, Cincinnati, Ohio
Director and Chief Executive
Jim Chmiel, MD, MPH
Biomedical
Informatics and
Clinical Data
Management
Systems
Committee
(formerly ODP WG)
Chair
Philip Payne
Study
WG
Committee
(Chmiel)
Business
Development
(Ruscio)
Clinical Trials
Operations
(Hilliard)
Clinical and
Translational
Science Awards
Committee
CTSA Directors
and CRUs
Pediatrics WG
Chair
JP Clancy
PBRN WG
Chair
Jim
Werner
Oncology WG
Ohio Clinical Trials Collaborative Organizational Chart
Research
Administration
Committee
(Formerly IRB WG)
Chair: Phil Cola
Executive Leadership Group
Pamela Davis, MD, PhD CWRU
James Heubi, MD UC Rebecca Jackson, MD OSU
OCTC Director and Chief Executive
James Chmiel, MD, MPH
OCTC
Operations
(Peter)
External Advisory Committee
OCTC Central Staff
Director, Global Business Development: Bruce Ruscio, Dr PH (interim)
Manager of Network Operations: Joseph Peter, MA, MBA, PMP
Manager of Clinical Trials Operations: Kathleen Hilliard, BA, CCRC
Global
Communications
and Marketing
IRB
Study
Contracting
Study
Implementation and
Conduct WG
Chair: K. Hilliard
Study
Budgets
Performance
Monitoring
Study
Management
Quality Assurance
and Process
Improvement
Administrative
and Business
Management
Network
Communications
Meeting
Coordination
Education and Training
Government Relations + Strategic Initiatives
Bede Littman - State Contracts
Federal and State Funding Opportunities
Business
Solicitation and
Relations
MEMBERS CONFIRMED • Andrew Dahlem, PhD, Eli Lilly • Charles Johnson, MD, PhD, Vertex • Steven Landau, MD, HealthCare Ventures, LLC • Katherine Matthay, MD, UCSF • Mark Raupp, MD, Quintiles • Victoria Tifft, MBA, ClinicalRM, CRO based in Hinckley, Ohio • Jill Van Dalfsen, BS, MT, Cystic Fibrosis Foundation
Therapeutics Development Network
External Advisory Committee
Ohio Clinical Trials Collaborative
Open Data Portal Philip Payne, PhD, OSU
Reliant IRB Phil Cola, CWRU
Oncology Clinical Research Network Stan Gerson, MD, CWRU
Pediatrics Clinical Research Network JP Clancy, MD, UC
Practice Based Research Network Jim Werner, PhD, MSSA, CWRU
Initial Statewide Working Groups
Ohio Clinical Trials Collaborative
Chair, Philip Payne, PhD, OSU
A combined technology platform + governance model that overcomes current challenges to the effective + timely use of Linked Open Data
• Identifies subjects for recruitment • Ensures that OCTC develops trials that are representative of desired
patient populations
• Allows for heath analytics and in silico studies
• Potentially helps to focus efforts to attract pharma because of unique disease/outcomes, etc.
• Serves as a resource for biotech development when linked to biorepositories, etc.
Biomedical Informatics and Clinical Data Management Systems
Open Data Portal
Ohio Clinical Trials Collaborative
Chair, Phil Cola, CWRU
IRB approval time from 72 days to 7-14 days • A common IT platform to exchange IRB documentation
• Facilitates review of protocols for approval at a primary site with rapid administrative review at each additional site
• Coordinates everything electronically
• Accelerates IRB approvals between institutions in Ohio
• Since July 2012, 22 protocols have gone through the reliant IRB. 6 multicity, 16 within the City of Cleveland
Reliant IRB
Ohio Clinical Trials Collaborative
The integrated network is disease agnostic. Initial focus areas:
•Oncology Clinical Research Network
•Pediatric Clinical Research Network
•Practice Based Research Network
Statewide Clinical Trials Network
Ohio Clinical Trials Collaborative
Chair, Jim Werner, PhD, MSSA, CWRU
Conducts clinical and comparative effectiveness research.
• Provides access to 277 medical practices
• Completed 2 requests for cost-estimates in less than 1 week
Practice Based Research Network
Ohio Clinical Trials Collaborative
• Case Comprehensive Cancer Center
• The Ohio State University Comprehensive Cancer Center
Oncology Clinical Research Network
Ohio Clinical Trials Collaborative
Pediatric Clinical Research Network
Chair, JP Clancy, MD, University of Cincinnati
• Cincinnati Children’s Hospital Medical Center (2nd in NIH funding), Nationwide Children’s Hospital (16th in NIH funding), Rainbow Babies and Children’s Hospital (7th in NIH funding)
• Development of NIH contract agreement templates for review by member institutions
• Development of CDA templates to facilitate information sharing across the Pediatric Network
• Pediatrics Network helped to attract March of Dimes funding
Ohio Clinical Trials Collaborative
Looking Forward
• Continue to identify and meet with industry, CROs, biotechs, etc.
• Engage OCTC External Advisory Committee
• Marketing and business development
• Initiate clinical trials
• Establish common OCTC contracting language/template
Ohio Clinical Trials Collaborative
Jim Chmiel
Cell: 216.212.7992
Joe Peter
OCTC Contact Information
Visit http://casemed.case.edu/ctsc/octc
Ohio Clinical Trials Collaborative
Thank You
Ohio Clinical Trials Collaborative Accelerating cures. Creating jobs.
Ohio Clinical Trials Collaborative
47
Cleveland Clinic
OSU Medical Center
Akron General
UC Health System
University Hospitals
Battelle
Nationwide Children’s
OhioHealth
Akron Children’s
Summa Health System
48
• 5 quarterly meetings of companies and hospital purchasing departments via WebEx platform
• 15 companies selected to present from applicant pool of 50
• Outcomes to date are modest: 30+ requests for more information, 11 direct introductions and a successful study
49
Keys to Success
• This is a sales opportunity
• Never sure who will be on the WebEx
• Provide good prep material
• Be brief, have questions of your own
50
Disclaimer: Only Ohio-based life science companies with market-ready (completed) or in-
market products and services are eligible.
To find out more visit: www.bioenterprise.com/contact/choose_ohio
Santa Ono, Ph.D.
President University of Cincinnati
Professor, UC Department of Pediatrics Ohio Pharmaceutical Initiative